kiniksa
announces
new
data
phase
trial
mavrilimumab
giant
cell
arteritis
presented
abstracts
session
american
college
rheumatology
convergence
mavrilimumab
reduced
increased
sustained
remission
phase
giant
cell
arteritis
clinical
trial
primary
secondary
efficacy
endpoints
achieved
statistical
significance
results
consistent
across
new
onset
relapsing
refractory
cohorts
hamilton
bermuda
globe
newswire
kiniksa
pharmaceuticals
nasdaq
knsa
kiniksa
biopharmaceutical
company
pipeline
assets
designed
modulate
immunological
pathways
across
spectrum
diseases
today
announced
new
data
global
phase
clinical
trial
mavrilimumab
giant
cell
arteritis
gca
presented
abstracts
session
american
college
rheumatology
acr
convergence
mavrilimumab
investigational
monoclonal
antibody
targets
granulocyte
macrophage
colony
stimulating
factor
receptor
alpha
primary
secondary
efficacy
endpoints
achieved
statistical
significance
consistent
trend
efficacy
across
new
onset
relapsing
refractory
cohorts
significant
unmet
need
safe
effective
giant
cell
arteritis
therapies
believe
mavrilimumab
upstream
inhibition
two
immune
pathways
implicated
giant
cell
arteritis
potential
provide
differentiation
current
standard
care
therapies
addressing
underlying
pathophysiology
disease
said
john
paolini
md
phd
chief
medical
officer
kiniksa
phase
giant
cell
arteritis
trial
mavrilimumab
superior
placebo
primary
secondary
efficacy
endpoints
sustained
remission
week
data
underscore
potential
mavrilimumab
offer
differentiated
treatment
option
patients
relapsing
refractory
disease
well
new
onset
maria
investigator
global
phase
trial
deliver
virtual
presentation
entitled
mavrilimumab
anti
receptor
α
monoclonal
antibody
reduces
time
flare
increases
sustained
remission
phase
trial
patients
giant
cell
arteritis
abstracts
session
monday
november
eastern
time
sebastian
investigator
phase
trial
randomized
patients
mavrilimumab
mg
placebo
biweekly
injected
subcutaneously
oral
corticosteroid
taper
patients
stratified
new
onset
relapsing
refractory
disease
primary
efficacy
endpoint
adjudicated
gca
flare
week
treated
patients
statistically
significant
hazard
ratio
median
week
could
estimated
mavrilimumab
recipients
due
low
number
flares
mavrilimumab
treatment
arm
median
placebo
recipients
weeks
lower
risk
flare
mavrilimumab
recipients
compared
placebo
recipients
secondary
efficacy
endpoint
sustained
remission
week
treated
patients
also
statistically
significant
sustained
remission
rate
week
percentage
points
higher
mavrilimumab
recipients
compared
placebo
recipients
study
powered
disease
cohorts
consistent
trend
efficacy
across
new
onset
relapsing
refractory
cohorts
new
onset
cohort
lower
risk
flare
mavrilimumab
recipients
compared
placebo
recipients
hazard
ratio
sustained
remission
rate
week
percentage
points
higher
mavrilimumab
recipients
compared
placebo
recipients
relapsing
refractory
cohort
lower
risk
flare
mavrilimumab
recipients
compared
placebo
recipients
hazard
ratio
sustained
remission
rate
week
percentage
points
higher
mavrilimumab
recipients
compared
placebo
recipients
mavrilimumab
serious
adverse
events
rates
adverse
events
mavrilimumab
recipients
placebo
recipients
similar
washout
safety
period
ongoing
additional
analyses
phase
trial
planned
next
steps
development
program
gca
informed
anticipated
discussions
food
drug
administration
fda
abstract
available
acr
website
table
submitted
acr
authors
publication
referenced
abstract
follows
table
inadvertently
omitted
online
posting
abstract
table
efficacy
week
time
flare
week
sustained
remission
week
total
mitt
population
mavrilimumab
mg
placebo
number
subjects
flare
n
primary
efficacy
endpoint
time
flare
weeks
week
median
ci
ne
ne
ne
ne
hazard
ratio
mavrilimumab
vs
placebo
ci
secondary
efficacy
endpoint
sustained
remission
week
ci
difference
proportions
ci
time
flare
week
sustained
remission
week
randomization
strata
relapsing
refractory
mavrilimumab
mg
placebo
mavrilimumab
mg
placebo
number
subjects
flare
n
primary
endpoint
time
flare
weeks
week
median
ci
ne
ne
ne
ne
ne
ne
ne
ne
hazard
ratio
mavrilimumab
vs
placebo
ci
secondary
endpoint
sustained
remission
week
ci
difference
proportions
ci
ne
estimable
method
used
estimate
survival
functions
treatment
arm
calculated
based
cox
model
treatment
covariate
stratified
randomization
strata
comparison
placebo
respect
time
flare
calculated
using
test
stratified
randomization
strata
survival
estimates
standard
error
ci
arm
ci
difference
sustained
remission
two
arms
using
normal
approximation
placebo
arm
reference
calculated
based
cox
model
treatment
covariate
comparison
placebo
respect
time
flare
calculated
using
test
subgroup
analyses
powered
significance
nominal
p
values
reported
fda
recently
granted
orphan
drug
designation
mavrilimumab
treatment
gca
kiniksa
intends
make
presentation
available
science
section
website
acr
embargo
lifts
kiniksa
also
evaluating
mavrilimumab
severe
pneumonia
hyperinflammation
enrolling
phase
portion
global
randomized
adaptive
design
phase
clinical
trial
additionally
company
expects
announce
data
randomized
study
fourth
quarter
hospital
clínic
university
barcelona
institut
investigacions
biomèdiques
august
pi
sunyer
idibaps
massachusetts
general
hospital
harvard
university
global
phase
clinical
trial
mavrilimumab
gca
randomized
global
phase
clinical
trial
mavrilimumab
gca
consists
screening
period
treatment
period
washout
safety
period
patients
age
years
active
gca
confirmed
temporal
artery
biopsy
imaging
erythrocyte
sedimentation
rate
esr
mm
hour
protein
crp
mg
dl
symptoms
gca
within
weeks
randomization
included
patients
required
achieved
remission
resolution
symptoms
esr
mm
hour
crp
mg
dl
prior
randomization
giant
cell
arteritis
giant
cell
arteritis
rare
chronic
inflammatory
disease
arteries
cranial
giant
cell
arteritis
typically
presents
headache
jaw
claudication
well
constitutional
symptoms
fever
fatigue
acute
events
include
permanent
vision
loss
diminished
blood
flow
eye
large
vessel
form
giant
cell
arteritis
affects
branches
aorta
supplying
trunk
limbs
currently
one
treatment
giant
cell
arteritis
adjunct
corticosteroid
taper
mavrilimumab
mavrilimumab
investigational
monoclonal
antibody
targets
mavrilimumab
dosed
patients
rheumatoid
arthritis
phase
clinical
studies
europe
achieved
primary
endpoints
efficacy
safety
kiniksa
lead
indication
mavrilimumab
gca
rare
inflammatory
disease
arteries
kiniksa
also
evaluating
mavrilimumab
pneumonia
hyperinflammation
fda
granted
orphan
drug
designation
mavrilimumab
gca
kiniksa
kiniksa
biopharmaceutical
company
focused
discovering
acquiring
developing
commercializing
therapeutic
medicines
patients
suffering
debilitating
diseases
significant
unmet
medical
need
kiniksa
product
candidates
rilonacept
mavrilimumab
vixarelimab
based
strong
biologic
rationale
validated
mechanisms
target
underserved
conditions
offer
potential
differentiation
pipeline
assets
designed
modulate
immunological
pathways
across
spectrum
diseases
information
please
visit
statements
information
contained
press
release
contains
statements
within
meaning
private
securities
litigation
reform
act
cases
identify
forward
looking
statements
terms
may
expect
plan
anticipate
could
intend
target
project
contemplate
believe
estimate
predict
potential
continue
negative
terms
similar
expressions
although
statements
contain
identifying
words
statements
contained
press
release
relate
matters
historical
fact
considered
statements
including
without
limitation
statements
regarding
mavrilimumab
potential
offer
treatment
option
patients
relapsing
refractory
disease
well
new
onset
disease
giant
cell
arteritis
gca
unmet
need
patients
gca
potential
provide
differentiation
current
standard
care
therapies
mavrilimumab
potential
address
underlying
pathophysiology
disease
presentation
data
study
upcoming
medical
conference
timing
data
clinical
trials
potential
clinical
stage
product
candidates
offer
differentiation
statements
based
management
current
expectations
statements
neither
promises
guarantees
involve
known
unknown
risks
uncertainties
important
factors
may
cause
actual
results
performance
achievements
materially
different
future
results
performance
achievements
expressed
implied
statements
including
without
limitation
following
impact
additional
data
us
studies
companies
potential
undesirable
side
effects
caused
mavrilimumab
potential
inability
replicate
later
clinical
trials
positive
results
earlier
studies
clinical
trials
impact
discussions
fda
development
program
gca
reliance
third
parties
manufacture
product
candidates
conduct
clinical
trials
perform
certain
regulatory
activities
product
candidates
drug
substance
drug
product
shortages
including
connection
engagement
manufacturing
organization
produce
mavrilimumab
beyond
current
inventory
potential
impact
pandemic
measures
taken
response
pandemic
changes
operating
plan
funding
requirements
existing
new
competition
ability
attract
retain
qualified
personnel
important
factors
discussed
caption
risk
factors
quarterly
report
form
filed
securities
exchange
commission
sec
august
reports
subsequently
filed
furnished
sec
could
cause
actual
results
differ
materially
indicated
statements
made
press
release
statements
represent
management
estimates
date
press
release
may
elect
update
statements
point
future
disclaim
obligation
even
subsequent
events
cause
views
change
statements
relied
upon
representing
views
date
subsequent
date
press
release
every
second
counts
kiniksa
investor
media
contact
mark
ragosa
mragosa
